Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Payables (2016 - 2025)

Historic Payables for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $4.7 million.

  • Anika Therapeutics' Payables fell 3046.29% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 3046.29%. This contributed to the annual value of $5.6 million for FY2024, which is 931.55% down from last year.
  • As of Q3 2025, Anika Therapeutics' Payables stood at $4.7 million, which was down 3046.29% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Payables ranged from a high of $10.0 million in Q1 2024 and a low of $4.7 million during Q3 2025
  • For the 5-year period, Anika Therapeutics' Payables averaged around $7.6 million, with its median value being $7.9 million (2023).
  • Its Payables has fluctuated over the past 5 years, first surged by 3146.71% in 2021, then crashed by 5226.14% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' Payables stood at $7.6 million in 2021, then increased by 18.88% to $9.1 million in 2022, then crashed by 31.74% to $6.2 million in 2023, then decreased by 9.32% to $5.6 million in 2024, then dropped by 15.76% to $4.7 million in 2025.
  • Its last three reported values are $4.7 million in Q3 2025, $4.8 million for Q2 2025, and $5.3 million during Q1 2025.